|Mr. Marvin L. White||Pres, CEO & Director||786.71k||N/A||1962|
|Mr. Jeffrey G. Lamothe||Sr. VP, CFO & Treasurer||550.56k||N/A||1966|
|Dr. Scott C. Stromatt||Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer||567.45k||N/A||1958|
|Mr. Randy Joe Maddux||Sr. VP of Operations & Chief Manufacturing Officer||N/A||N/A||1961|
|Dr. Jane A. Gross||Sr. VP & Chief Scientific Officer||N/A||N/A||1957|
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.